Margherita Ambrosini
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy.
Journal: Journal for immunotherapy of cancer
Published: July 03, 2026
Early- and advanced-stage MSI-H non-colorectal cancers: best management and challenges in 2025.
Journal: ESMO gastrointestinal oncology
Published: April 17, 2026
Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancer.
Journal: Journal of the National Cancer Institute
Published: February 19, 2026
Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer.
Journal: The oncologist
Published: February 10, 2026
Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis.
Journal: ESMO open
Published: January 16, 2026
From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 08, 2026
Consistency of Radiological Staging in Resectable Mismatch-Repair Proficient Colon Cancer: An Interobserver Agreement Study.
Journal: Clinical colorectal cancer
Published: October 17, 2025
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 29, 2025
ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 25, 2025
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 08, 2025
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer.
Journal: The oncologist
Published: May 08, 2025
Last Updated: 09/26/2026